8 reports of this reaction
2.3% of all METHENAMINE, SODIUM SALICYLATE reports
#7 most reported adverse reaction
CYSTITIS is the #7 most commonly reported adverse reaction for METHENAMINE, SODIUM SALICYLATE, manufactured by Aurobindo Pharma Limited. There are 8 FDA adverse event reports linking METHENAMINE, SODIUM SALICYLATE to CYSTITIS. This represents approximately 2.3% of all 348 adverse event reports for this drug.
Patients taking METHENAMINE, SODIUM SALICYLATE who experience cystitis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CYSTITIS is a less commonly reported adverse event for METHENAMINE, SODIUM SALICYLATE, but still significant enough to appear in the safety profile.
In addition to cystitis, the following adverse reactions have been reported for METHENAMINE, SODIUM SALICYLATE:
The following drugs have also been linked to cystitis in FDA adverse event reports:
CYSTITIS has been reported as an adverse event in 8 FDA reports for METHENAMINE, SODIUM SALICYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CYSTITIS accounts for approximately 2.3% of all adverse event reports for METHENAMINE, SODIUM SALICYLATE, making it a notable side effect.
If you experience cystitis while taking METHENAMINE, SODIUM SALICYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.